The researchers found that CD133+ tumor cells derived from human glioma xenografts and glioblastoma tissue collected after surgery trigger the DNA damage checkpoint more efficiently than CD133-negative tumor cells. The gene discussed is PROM1; the disease is central nervous system cancer.